Author: CSL

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

October 4, 2026
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

July 27, 2026

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases